Eribulin Mesylate

Overview

Eribulin Mesylate (CAS: 441045-17-6) is a potent microtubule-targeting agent and synthetic analog of halichondrin B. It disrupts microtubule growth, causing cell cycle arrest and apoptosis. Eribulin is FDA-approved for treating metastatic breast cancer and liposarcoma and is also explored in antibody-drug conjugates (ADCs) for targeted cancer therapy.

Application

Payloads and Linker modified Payloads

Product Information

• Catalog No.: AP15212
• CAS No.: 441045-17-6
• Molecular Formula: C41H63NO14S
• Molecular Weight: 826.00
• Purity: ≥95%
• Availability: In Stock

Source

Original product source